Kura Oncology (KURA) Non-Current Assets (2014 - 2026)

Kura Oncology (KURA) has 13 years of Non-Current Assets data on file, last reported at $28.8 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $28.8 million, up 47.04% year-over-year; the trailing twelve-month figure through Mar 2026 was $109.5 million (up 66.24% YoY), and the FY2025 annual result was $29.7 million, up 93.74% from the prior year.
• Non-Current Assets eased to $28.8 million in Q1 2026 per KURA's latest filing, from $29.7 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $29.7 million in Q4 2025 and troughed at $9.1 million in Q2 2023.
• A 5-year average of $16.8 million and a median of $15.3 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets declined 21.89% in 2023, then soared 93.74% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $9.9 million in 2022, then soared by 66.54% to $16.5 million in 2023, then decreased by 6.83% to $15.3 million in 2024, then soared by 93.74% to $29.7 million in 2025, then dropped by 3.13% to $28.8 million in 2026.
• Business Quant data shows KURA's Non-Current Assets at $28.8 million in Q1 2026, $29.7 million in Q4 2025, and $28.7 million in Q3 2025.